Target Name: GET1
NCBI ID: G7485
Review Report on GET1 Target / Biomarker Content of Review Report on GET1 Target / Biomarker
GET1
Other Name(s): CHD5 | Congenital heart disease 5 protein | guided entry of tail-anchored proteins factor 1 | tryptophan-rich protein | tail-anchored protein insertion receptor WRB | Guided entry of tail-anchored proteins factor 1, transcript variant 1 | congenital heart disease 5 protein | Guided entry of tail-anchored proteins factor 1 (isoform 2) | GET1 variant 1 | WRB | Guided entry of tail-anchored proteins factor 1 (isoform 1) | Guided entry of tail-anchored proteins factor 1 | Tryptophan-rich basic protein | GET1_HUMAN | WRB_HUMAN | tryptophan rich basic protein | Guided entry of tail-anchored proteins factor 1, transcript variant 2 | tryptophan-rich basic protein | GET1 variant 2

GET1: A Protein Targeted for Cancer and Other Diseases

GET1 (CHD5) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In recent years, GET1 has emerged as a promising drug target for the treatment of various diseases, including cancer, due to its unique biology and the potential for its inhibition to lead to a wide range of therapeutic effects.

The GET1 protein is composed of 514 amino acids and has a molecular weight of 61 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is involved in the regulation of cell proliferation, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). GET1 is a critical regulator of cell proliferation and has been shown to play a role in the development and progression of a number of diseases, including cancer.

One of the key functions of GET1 is its role in cell proliferation. GET1 has been shown to be involved in the regulation of cell cycle progression and in the establishment of the G1/S transition, which is a critical step in the cell cycle that allows for cell growth and division. In addition, GET1 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. GET1 has been shown to promote the apoptosis of certain cell types, such as cancer cells, and may be a potential therapeutic target for the treatment of cancer.

Another function of GET1 is its role in angiogenesis. GET1 has been shown to be involved in the regulation of blood vessel formation and may play a role in the development of new blood vessels in the process of angiogenesis. This may be of particular interest in the treatment of diseases that are characterized by the buildup of plaque in the blood vessels, such as heart disease. By inhibiting GET1 activity, researchers may be able to reduce the formation of new blood vessels and improve blood flow to the affected area, leading to a reduction in the risk of further damage.

In addition to its functions in cell proliferation and angiogenesis, GET1 has also been implicated in a number of other biological processes. For example, GET1 has been shown to play a role in the regulation of protein synthesis and may be involved in the regulation of compromise( homeostasis) of cellular processes. In addition, GET1 has been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which plays a critical role in the regulation of cell growth and differentiation.

The therapeutic potential benefits of GET1 are vast and varied. In addition to its potential as a drug target for the treatment of cancer, GET1 may also be a useful biomarker for the detection and diagnosis of various diseases. For example, GET1 has been shown to be involved in the regulation of cell proliferation and may be a useful marker for the diagnosis of neurodegenerative diseases, such as Alzheimer's disease. In addition, GET1 may be a useful biomarker for the diagnosis of certain autoimmune disorders, such as rheumatoid arthritis.

In conclusion, GET1 is a protein that is involved in a number of important biological processes and has been implicated in a variety of diseases. Its unique biology and potential as a drug target make GET1 an attractive target for the development of new therapeutic approaches for the treatment of a wide range of diseases. Further research is needed to fully understand the functions of GET1 and its potential as a therapeutic target.

Protein Name: Guided Entry Of Tail-anchored Proteins Factor 1

Functions: Required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum (ER) (PubMed:21444755, PubMed:23041287, PubMed:24392163, PubMed:27226539). Together with CAMLG/GET2, acts as a membrane receptor for soluble GET3/TRC40, which recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol (PubMed:21444755, PubMed:23041287, PubMed:24392163, PubMed:27226539). Required to ensure correct topology and ER insertion of CAMLG (PubMed:31417168, PubMed:32187542)

The "GET1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GET1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GET3 | GET4 | GFAP | GFER | GFI1 | GFI1B | GFM1 | GFM2 | GFOD1 | GFOD2 | GFPT1 | GFPT2 | GFRA1 | GFRA2 | GFRA3 | GFRA4 | GFRAL | GFUS | GGA1 | GGA2 | GGA3 | GGACT | GGCT | GGCX | GGH | GGN | GGNBP1 | GGNBP2 | GGPS1 | GGT1 | GGT2P | GGT3P | GGT5 | GGT6 | GGT7 | GGT8P | GGTA1 | GGTLC1 | GGTLC2 | GGTLC3 | GH1 | GH2 | GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3